Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract.
OBJECTIVE
The purpose of this study was to evaluate the results of phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in patients with diabetic clinically significant macular edema and cataract.


METHODS
The records of 22 diabetic patients, with clinically significant macular edema and cataract who have undergone phacoemulsification with intravitreal injection of 1.25 mg bevacizumab and 2 mg triamcinolone acetonide, were retrospectively evaluated. All patients have undergone focal or modified grid argon laser photocoagulation 1 month after the surgery. All patients were evaluated by spectral OCT/OCT SLO before, 1 month, and 3 months after the surgery. The main parameters were the best-corrected visual acuity (BCVA) and central macular thickness (CMT). Paired samples t-test was used for statistical analysis.


RESULTS
The mean initial best-corrected visual acuity was 0.15 ± 0.09 (0.05-0.3), whereas it was 0.6 ± 0.28 (SD) (0.3-0.7), 0.6 ± 0.22 (SD) (0.4-0.7) at 1 month and 3 months after the surgery, respectively. The BCVA levels recorded at 1 month and 3 months after the surgery were significantly higher than the initial BCVA (P = 0.002). The mean initial CMT was 392.2 ± 109.5 μm, whereas it was 295 ± 57.2 μm and 265.5 ± 30.3 μm at 1 month and 3 months after the surgery, respectively. The CMT values recorded at 1 month and 3 months after the surgery were significantly lower than the initial CMT (P < 0.001, P < 0.001).


CONCLUSIONS
Phacoemulsification with intravitreal injection of bevacizumab and triamcinolone acetonide provides a decrease in CMT with a gain in BCVA in diabetic patients with clinically significant macular edema and cataract.
Department Of Retina, Kudret Eye Hospital, Ankara, Turkey.
Arsen
A
Akinci
Orkun
O
Muftuoglu
Alı
A
Altınsoy
Ersel
E
Ozkılıc
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D002386:Cataract / Q000150:complications* / Q000503:physiopathology; D003131:Combined Modality Therapy; D003930:Diabetic Retinopathy / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D058449:Intravitreal Injections; D019654:Lens Implantation, Intraocular; D008266:Macula Lutea / Q000473:pathology; D008269:Macular Edema / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide